Dabrafenib, in combination with trametinib, is indicated for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.
|NCPE Assessment Process||Complete|
|Rapid Review commissioned||30/01/2019|
|Rapid Review completed||21/03/2019|
|Rapid Review Outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dabrafenib plus trametinib (Tafinlar® plus Mekinist®) compared with the current standard of care.
|Full pharmacoeconomic assessment commissioned by HSE||09/04/2019|
|Pre-submission consultation with Applicant||28/05/2019|
|Submission received from Applicant||02/09/2019|
|Preliminary review sent to Applicant||09/04/2020|
|NCPE assessment re-commenced||18/05/2020|
|Factual accuracy check sent to Applicant||10/07/2020|
|NCPE assessment re-commenced||20/07/2020|
|NCPE assessment completed||19/08/2020|
|NCPE assessment outcome||The NCPE recommend that dabrafenib and trametinib be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.